EZH2 and prostate cancer: The aim of this study was to assess the association between H3K27me3 level and prostate cancer risk and the correlation of H3K27me3 on EZH2, RAR beta 2, ER alpha, PGR, and RGMA promoters with clinicopathological variables including Gleason score, PSA levels and clinical stages.